RDD Blog » Uncategorized

R&D Directions Insider

Archive for the ‘ Uncategorized ’ Category

Adding to the tally …

Thursday, July 14th, 2011

In case you missed it, two more acquisitions in the CRO space were completed this week. Today, InVentiv Health finalized its deal to buy PharmaNet Development Group (InVentiv added i3 in June). On Tuesday, INC Research sealed its $232 million acquisition of Kendle International Inc. These deals are just the latest ...

Posted in CRO, Uncategorized | No Comments »

2011 Dealmakersâ€™ Intentions Study sees trend toward early-stage licensing activity

Thursday, June 30th, 2011

In a super session at the 2011 BIO International Convention yesterday in Washington D.C., Ben Bonifant of Campbell Alliance presented the results of the companyâ€™s third annual Dealmakersâ€™ Intentions Survey. Business development professionals from pharmaceutical and biotechnology companies of all sizes were surveyed on their general expectations for deal activity ...

Posted in Uncategorized | No Comments »

ASCO followup: Patients, pathways, progress in practice

Monday, June 27th, 2011

(This is a guest post from Sally Church, Ph.D, who writes the Pharma Strategy Blog. If you are on Twitter, follow her here.) Traditionally, we have seen virtually all of the early drug development work in oncology driven by a myriad of company trials in various tumor types and, increasingly, molecular ...

Posted in Uncategorized | 2 Comments »

Pfizer pacts are further proof of CRO shift

Wednesday, June 8th, 2011

Itâ€™s no secret Pfizer, perhaps more than any other big pharma, is looking to â€œgain efficienciesâ€ in R&D at every turn. Gaining efficiencies, of course, is just a fancy way of describing the need to cut costs, which it appears Pfizer, as it looks to divest many of its businesses, ...

Posted in CRO, Uncategorized, clinical trials | No Comments »

INC exec: Global scale-up key driver of Kendle deal

Friday, May 13th, 2011

We caught up with INC Researchâ€™s chief operating officer John Potthoff, Ph.D., by email for more on INCâ€™s big deal to acquire CRO rival Kendle, a move that could elevate the privately held company into a top five industry player. R&D Directions: How will the acquisition of Kendle position INC ...

Posted in CRO, Uncategorized, clinical trials | No Comments »

Patent reform inches closer to reality

Monday, May 2nd, 2011

If at first you donâ€™t succeed, try, try, try, and try again. Such has been the case in Congressâ€™ quest to reform U.S. patent law, where after stalled attempts in 2005, 2007, and 2009, seems to finally be gaining the momentum it really needs in 2011. The Patent Reform Act of ...

Posted in Uncategorized | No Comments »

Show us the data! Economists tackle clinical trial cost triggers

Wednesday, April 13th, 2011

After hearing the recent news that the National Bureau of Economic Research is investigating the rising costs of drug development, you might be wondering why the non-profit group is even taking a stab at what has long been a difficult area to pin down statistically. While it is well documented ...

Posted in Uncategorized, clinical trials | No Comments »

Drug repositioning a timely strategy

Monday, December 27th, 2010

With patent expirations looming for several major pharmaceutical companies, the practice of drug repositioning is becoming increasingly important. Drugmakers, also faced with declining R&D productivity levels and an increasingly rigorous regulatory environment, are focused on identifying novel indications and disease targets for existing compounds and securing patent protection before their ...

Posted in Uncategorized, clinical trials, drug discovery | No Comments »

Biosimilars picture has â€˜so many unknownsâ€™

Thursday, November 18th, 2010

I donâ€™t know about you, but I canâ€™t get enough biosimilars talk these days (thereâ€™s a sentence I thought I would never write). FDAâ€™s two-day hearing earlier this month featured many opinions, and though most didnâ€™t stray too far from party lines (hereâ€™s the official releases from BIO, PhRMA, GPhA, ...

Posted in Uncategorized | No Comments »

Behind the NICE Alzheimer’s reversal

Friday, November 5th, 2010

You may be wondering what convinced the National Institute for Health and Clinical Excellence, U.K.â€™s controversial drug-cost watchdog, to reverse its restrictions on four top Alzheimerâ€™s disease medicines last month, opening up potential access to hundreds of thousands of sufferers previously denied coverage. No, it doesnâ€™t appear the result of a ...

Posted in CRO, Uncategorized | No Comments »

©2012 UBM Canon